Haleon plc (LON:HLN) Receives GBX 393.67 Consensus Target Price from Brokerages

Shares of Haleon plc (LON:HLN) have received an average recommendation of “Hold” from the six research firms that are presently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is GBX 393.67.

A number of research firms have recently weighed in on HLN. Berenberg Bank reaffirmed a “buy” rating and set a GBX 512 price target on shares of Haleon in a research note on Thursday, April 30th. JPMorgan Chase & Co. lowered their price target on Haleon from GBX 335 to GBX 315 and set an “underweight” rating for the company in a research note on Thursday, June 25th. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a GBX 370 price objective on shares of Haleon in a research report on Thursday, April 30th. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating and issued a GBX 325 target price on shares of Haleon in a research note on Wednesday, July 1st. Finally, Jefferies Financial Group decreased their target price on shares of Haleon from GBX 450 to GBX 400 and set a “buy” rating for the company in a research report on Tuesday, May 5th.

Haleon Price Performance

HLN opened at GBX 363.10 on Thursday. The stock has a market cap of £31.98 billion, a price-to-earnings ratio of 19.63, a PEG ratio of 1.49 and a beta of 0.24. Haleon has a 1 year low of GBX 317.80 and a 1 year high of GBX 416.10. The company has a current ratio of 0.92, a quick ratio of 0.93 and a debt-to-equity ratio of 52.26. The stock has a fifty day moving average price of GBX 345.37 and a 200 day moving average price of GBX 363.17.

About Haleon

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.